The Argument Against a Biosimilar Switch Policy for Infliximab in Patients with Inflammatory Bowel Disease Living in Alberta

A nonmedical switch policy is currently being considered in Alberta, which would force patients on originator biologics to biosimilar alternatives with the hypothetical aim of reducing costs to the health care system. The evidence to support the safety of nonmedical switching in patients with inflam...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, Gilaad G, Ma, Christopher, Seow, Cynthia H, Kroeker, Karen I, Panaccione, Remo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465546/
https://www.ncbi.nlm.nih.gov/pubmed/32905124
http://dx.doi.org/10.1093/jcag/gwz044

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7465546/
https://www.ncbi.nlm.nih.gov/pubmed/32905124
http://dx.doi.org/10.1093/jcag/gwz044

Ejemplares similares